Method for converting echinocandin B by using microbial enzyme

Abstract

The invention provides a method for converting echinocandin B (ECB) by using microbial enzyme. The method comprises the steps that: (1) microbes are fermented, such that echinocandin B deacylase is obtained; (2) when fermentation is finished, phosphate is added into the fermentation broth; ultrasonic processing is carried out; and supernatant is obtained by centrifugation, and the supernatant is echinocandin B deacylase crude enzyme solution; (3) the crude enzyme solution is purified, such that echinocandin B deacylase enzyme solution is obtained; (4) echinocandin B is dissolved in ethanol, and is mixed with the deacylase enzyme solution; mixing and stirring are carried out, such that the material is converted into echinocandins B nucleus; when conversion is finished, filtering is carried out; and the filtrate is obtained; and (5) the filtrate is processed by using macroporous adsorption resin; echinocandins B nucleus is absorbed on resin; and echinocandins B nucleus is eluted by using an organic solvent. According to the invention, a molar conversion rate is high, a conversion time is short, an obtained product is easy to separate and to purify, and ECB deacylase can be repeatedly used.

Description

technical field

[0001] The invention relates to the field of biopharmaceuticals, more specifically, the invention relates to a method for converting echinocandin B into echinocandin B mother nucleus by microbial enzymes. Background technique

[0002] Since the 1970s, the frequency and types of fungal infections have been increasing, especially in immunosuppressed patients including HIV-infected patients, organ transplant recipients, cancer patients and those with other diseases who are undergoing immunotherapy of patients. Until the successful development of imidazole and triazole antifungal drugs in the late 1980s and 1990s, fungal infections could be effectively and safely controlled clinically. Although these drugs have played an important role in the control of clinical deep fungal infections, due to the poor selectivity of these drugs, the emergence of drug-resistant fungi, and the low sensitivity to fungi such as Aspergillus and Candida albicans, the incidence of deep...

Images